124 completed, 20 recruiting, 11 not yet recruiting, 11 unknown. 78 Phase 1, 28 Phase 3, 24 Phase 2, 12 Phase 4, 2 Not applicable.
Follow Boryung Pharmaceutical Co., Ltd: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dapagliflozin for Anemia in Lower-Risk Myelodysplastic Syndromes Dapagliflozin (10mg Tab) - Myelodysplastic Syndromes (MDS), Anemia | Phase 2 | Not yet recruiting | Seug yun Yoon, MD | 37 | 2026-09-01 | 2026-04-08 |
| To Evaluate the Renal Protective Effects and Safety of 'Fimasartan and Atorvastatin' or 'Fimasartan, Atorvastatin and Ezetimibe'. Essential Hypertension, Primary Hypercholesterolemia | Not yet recruiting | Boryung Pharmaceutical Co., Ltd | 12700 | 2026-08-01 | 2026-07-06 | |
| A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-3 and BR1015-2 Under Fed Conditions BR1015-A, BR1015-3, BR1015-2 - Essential Hypertension | Phase 1 | Not yet recruiting | Boryung Pharmaceutical Co., Ltd | 48 | 2026-04-19 | 2026-02-19 |
| A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-3 and BR1015-2 Under Fasting Conditions BR1015-A, BR1015-3, BR1015-2 - Essential Hypertension | Phase 1 | Not yet recruiting | Boryung Pharmaceutical Co., Ltd | 58 | 2026-04-13 | 2026-02-19 |
| A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-1 and BR1015-2 Under Fed Conditions BR1015-A, BR1015-1, BR1015-2 - Essential Hypertension | Phase 1 | Not yet recruiting | Boryung Pharmaceutical Co., Ltd | 48 | 2026-04-09 | 2026-02-19 |
| A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-1 and BR1015-2 Under Fasting Conditions BR1015-A, BR1015-1, BR1015-2 - Essential Hypertension | Phase 1 | Not yet recruiting | Boryung Pharmaceutical Co., Ltd | 58 | 2026-04-02 | 2026-02-19 |
| Lenvatinib or Regorafenib for Advanced Hepatocellular Carcinoma After Immunotherapy (REVIVE) Lenvatinib, regorafenib - Hepatocellular Carcinoma (HCC) | Phase 2 | Not yet recruiting | Asan Medical Center | 146 | 2026-04-01 | 2026-05-27 |
| Regorafenib After Treatment Failure of First Line Immune Checkpoint Inhibitor Treatment in Advanced Hepatocellular Carcinoma Patients Regorafenib (BAY 73-4506) - Carcinoma, Hepatocellular, Hepatic Insufficien | Phase 2 | Not yet recruiting | Ju Hyun Shim | 20 | 2026-03-15 | 2026-04-07 |
| Regorafenib After Failure of Lenvatinib in Patients With Unresectable HCC: The RELEVANT-HCC Trial Regorafenib (BAY 73-4506) - Carcinoma, Hepatocellular, Lenvatinib | Phase 2 | Not yet recruiting | Ju Hyun Shim | 24 | 2026-03-15 | 2026-04-07 |
| A Study of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 in Patients With Essential Hypertension BR1400-1, BR1400-2, BR1400-3 - Essential Hypertension | Phase 2 | Not yet recruiting | Boryung Pharmaceutical Co., Ltd | 330 | 2026-03-01 | 2026-01-28 |
| Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy Trastzumab Deruxtecan, Bevacizumab, Platinum Based Chemotherapy - Ovarian Cancer, Ovarian Carcinoma, Recurrent | Phase 2 | Recruiting | Yonsei University | 116 | 2026-02-26 | 2026-04-20 |
| A Study of Bosmolisib (BR101801) in Participants With R/R PTCL. BR101801 - Peripheral T Cell Lymphoma | Phase 2 | Not yet recruiting | Boryung Pharmaceutical Co., Ltd | 44 | 2026-02-01 | 2026-01-28 |
| A Study of Second- and Later-line Palliative Chemotherapy in Patients With Metastatic Colorectal Cancer. Second and later-line palliative chemotherapy - Metastatic Colorectal Cancer | Recruiting | Boryung Pharmaceutical Co., Ltd | 1000 | 2025-11-07 | 2025-12-04 | |
| A Study of Olanzapine in Participants With Bipolar Disorder. Olanzapine - Bipolar Disorder | Recruiting | Boryung Pharmaceutical Co., Ltd | 3000 | 2025-10-30 | 2025-12-04 | |
| A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fed) Dapagliflozin 10 mg/Pioglitazone 30 mg/Metformin HCl 1000 mg, Dapagliflozin 10 mg, Pioglitazone 30 mg - Diabete Mellitus | Phase 1 | Recruiting | Boryung Pharmaceutical Co., Ltd | 40 | 2025-07-05 | 2025-07-24 |
| A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fasting) Dapagliflozin 10 mg/Pioglitazone 30 mg/Metformin HCl 1000 mg, Dapagliflozin 10 mg, Pioglitazone 30 mg - Diabetes Mellitus | Phase 1 | Recruiting | Boryung Pharmaceutical Co., Ltd | 52 | 2025-07-03 | 2025-07-24 |
| A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Olaparib 150 MG - Ovarian Cancer | Phase 1 | Recruiting | Boryung Pharmaceutical Co., Ltd | 24 | 2025-06-17 | 2025-07-16 |
| A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes Metformin, Dapagliflozin/Pioglitazone, Dapagliflozin/Sitagliptin - Type 2 Diabetes | Phase 4 | Recruiting | Boryung Pharmaceutical Co., Ltd | 204 | 2025-06-11 | 2025-09-15 |
| A Clinical Trial to Evaluate the Safety and Efficacy of Olanzapine Titration Schedule in Patients With Schizophrenia BR5402A, BR5402A-1, BR5402B - Schizophrenia | Phase 2 | Recruiting | Boryung Pharmaceutical Co., Ltd | 120 | 2025-05-30 | 2025-09-15 |
| A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1018 and Coadministration of BR1018A and BR1018B in Healthy Adult Volunteers BR1018, BR1018A, BR1018B - Essential Hypertension, Primary Hypercholesterolemia | Phase 1 | Completed | Boryung Pharmaceutical Co., Ltd | 60 | 2025-05-07 | 2025-09-12 |
Showing 20 of 172. Sign in to see all of them.
Essential Hypertension (43) · Hypertension (43) · Diabetes Mellitus, Type 2 (13) · Diabetes Mellitus (7) · Hyperlipidemias (6) · Carcinoma, Hepatocellular (5) · Ovarian Neoplasms (5) · Dyslipidemias (4) · Duodenal Ulcer (3) · Hepatitis (3) · Ischemic Stroke (3) · Stomach Neoplasms (3) · Breast Neoplasms (2) · Colonic Neoplasms (2) · Encephalitis, Japanese (2)
fimasartan (55) · Amlodipine (9) · Rosuvastatin Calcium (8) · Atorvastatin (7) · dapagliflozin (6) · Pioglitazone (5) · Valsartan (5) · Bevacizumab (4) · Hydrochlorothiazide (4) · Cisplatin (3) · Drug Therapy (3) · Indapamide (3) · Metformin (3) · Paclitaxel (3) · lafutidine (3)
South Korea (146) · Indonesia (1) · Russia (1) · Thailand (1) · United States (1)
Myung Sook Hong (5) · MyungSook Hong (4) · An-Hye Kim (3) · E Engmann, MB ChB (2) · Kyung-Sang Yu, MD (2) · Myung-Sook Hong (2) · Sang-Heon Cho (2) · An-Hye Kim, M.D. Ph.D (1) · Byung-He Oh, Professor (1) · Byung-He Oh, professor (1) · Byung-Hee Oh, MD (1) · Byung-Hee Oh, Professor (1) · Chang Woo Kim, MD, PhD (1) · Chang Wook Nam, Professor (1) · Chang-Min Seong (1)
PMID 21740078, PMID 22608107, PMID 10639539, PMID 10912743, PMID 11897754, PMID 11937179, PMID 12135313, PMID 12493255, PMID 12623974, PMID 14581662, PMID 14656957, PMID 15879332, PMID 16034448, PMID 16448896, PMID 16476843, PMID 17179034, PMID 17253471, PMID 17337887, PMID 17485598, PMID 17510503, PMID 18268136, PMID 18839172, PMID 19628800, PMID 19817870, PMID 19850215, PMID 20228403, PMID 20838053, PMID 21183747, PMID 21316752, PMID 21394036, PMID 21597296, PMID 21765368, PMID 22381711, PMID 22727611, PMID 23932463, PMID 24084213, PMID 25092393, PMID 25567119, PMID 25850881, PMID 26082615, PMID 26257511, PMID 27161546, PMID 27502326, PMID 28057081, PMID 29284530, PMID 29429815, PMID 29739356, PMID 30126861, PMID 30186623, PMID 31262348